Medigene Receives Further European Patent on EndoTAG®-1
(Thomson Reuters ONE) -
Medigene AG /
Medigene Receives Further European Patent on EndoTAG®-1
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Martinsried/Munich, 29 May 2013. Medigene AG (Frankfurt, Prime Standard; MDG)
announced today that the European Patent Office has granted a further patent
which protects the drug candidate EndoTAG(®)-1. The term of the patent EP
2108362 entitled "A cationic liposomal preparation comprising a taxane" ends on
June 26, 2023.
Dr. Frank Mathias, Chief Executive Officer of Medigene AG: "The new patent
strengthens the patent position for EndoTAG(®)-1 in Europe. We will continue to
extend our patent portfolio to ensure protection of the EndoTAG(®)-1 product for
Medigene and our partner SynCore."
About EndoTAG(®)-1: The clinical drug candidate EndoTAG(®)-1 is a novel
composition of the established cytostatic drug paclitaxel combined with neutral
and positive lipids. Because of the positively charged lipids, EndoTAG(®)-1
interacts with newly developed, negatively charged endothelial cells, which are
particularly required for the generation of tumor blood vessels. The EndoTAG(®)-
1 paclitaxel component attacks the endothelial cells as they divide, thus
targeting the blood supply to tumors without affecting the blood supply to
healthy tissue. By doing this, EndoTAG(®)-1 is expected to prevent the formation
of new tumor blood vessels and to inhibit tumor growth. Medigene has
successfully completed two clinical phase II trials of EndoTAG(®)-1 in
pancreatic cancer and triple-negative breast cancer (TNBC). The drug candidate
has also shown positive results in a recently concluded investigator-initiated
trial (IIT) in HER2-negative breast cancer.
Medigene AG (Frankfurt: MDG, prime standard) is a publicly listed biotechnology
company headquartered in Martinsried/Munich, Germany. Medigene focuses on
clinical research and development of novel drugs against cancer and autoimmune
diseases. Medigene is the first German biotech company to have revenues from a
marketed product (Veregen(®)), which is distributed by partner companies.
Medigene has two drug candidates in clinical trials, EndoTAG(®)-1 and RhuDex(®),
and is developing an innovative vaccine technology. For more information, please
visit www.medigene.com.
This press release contains forward-looking statements representing the opinion
of Medigene as of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking statements made
herein. Medigene is not bound to update any of these forward-looking statements.
Medigene(®) and EndoTAG(®) are registered trademarks of Medigene AG. These
trademarks may be owned or licensed in select locations only.
Contact
Julia Hofmann, Claudia Burmester
Investor & Public Relations
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor(at)medigene.com
To unsubscribe from the press release distribution list, please go to
www.medigene.com/unsubscribe.
Press release as PDF:
http://hugin.info/132073/R/1705294/564079.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Medigene AG via Thomson Reuters ONE
[HUG#1705294]
Unternehmensinformation / Kurzprofil:
Datum: 29.05.2013 - 07:30 Uhr
Sprache: Deutsch
News-ID 264130
Anzahl Zeichen: 4069
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 265 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medigene Receives Further European Patent on EndoTAG®-1"
steht unter der journalistisch-redaktionellen Verantwortung von
Medigene AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
